| [1] |
BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe.
Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14.
|
| [2] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
| [3] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
| [4] |
SHA Mingquan, ZHANG Yawei, ZHOU Hongjie, WEN Baoshu.
A comparative progress and prospect for drug technological guidances system in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1045-1049.
|
| [5] |
TAN Jing, LIU Chunrong, HUANG Shiyao, GAO Pei, WANG Yang, LI Chen, HE Yong, YUAN Hong, WANG Wen, LI Ling, XIONG Yiquan, REN Yan, YAO Minghong, ZHAO Yan, DONG Fang, SHEN Chuanyong, SUN Xin.
Expert consensus on post-marketing risk monitoring technology for high-risk implantable passive medical devices based on real world data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 13-17.
|
| [6] |
ZHENG Chao, WU Yan, ZHANG Lan, HU Kai, ZENG Ye, WANG Wen, WANG Ling.
Methods for risk trend analysis of EU post-marketing surveillance for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 79-82.
|
| [7] |
SHA Mingquan, Li Yiyun, WEN Baoshu.
Pharmaceutical Patent Information under the Framework of American Orange Book
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 817-820.
|
| [8] |
MAO Zhenbin, LIU Shuyu.
Implications of Regulatory Science for the Construction of Medical Device Vigilance Systems
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 601-605.
|
| [9] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|
| [10] |
TIAN Yi, YANG Yue, TIAN Li-juan.
Study and Enlightenment of Medicines Risk Management Plan in European Union
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(9): 529-532.
|
| [11] |
LIN Jie, SHI Wen-Hui, SUN Zhi-ming, BA Lei, ZHOU Jian, XU Hao-qin, CHEN Ying, YAO Jie.
Analysis of the Side Effects of Contraceptives in the First-diagnosed Registration and Follow-up System in Jiangsu Province
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 47-59.
|
| [12] |
ZHANG Chen-guang,LIU Yan,XU Wei.
Research and Countermeasure for Information Safety of Intelligent Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(6): 363-365.
|
| [13] |
SONG Yang,YU Zhi-bin,YANG Yue.
Research of Traditional Chinese Medicine Registered as Botanical New Drug in America
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(4): 219-223.
|
| [14] |
CHEN Ying，ZHU Xiang-jun，ZHOU Jian，BA Lei，YAO Jie，SUN Zhi-ming，LI Ying.
Pareto Diagram Analysis on Initial Registration and Follow-up of Contraceptives
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(2): 114-116.
|
| [15] |
LIN Ni, JIN Hong-tao, WANG Ai-ping.
Progress in Safety Evaluation and Usage of Plasticizers in Medical Devices
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(2): 100-103.
|
